Canagliflozin
HR+ HER2- Breast Cancer
Faeth TherapeuticsSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the HR+ HER2- Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT Faeth Therapeutics | Phase 1/2 | CCC |
Tak-228 Faeth Therapeutics | Phase 1/2 | CC |
Serabelisib Faeth Therapeutics | Phase 1/2 | CC |
nkt5097 cdk2/cdk4 dual degrader NiKang Therapeutics, Inc. | Phase 1 | CC |
Letrozole NiKang Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
Canagliflozin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →